Annals of Hematology

, Volume 90, Issue 10, pp 1241–1243 | Cite as

CML with e6a2 BCR-ABL1 transcript: an aggressive entity?

  • Karolien Anne Beel
  • Jan Lemmens
  • Hilde Vranckx
  • Johan Maertens
  • Peter Vandenberghe
Letter to the Editor

Dear Editor,

The BCR-ABL1 fusion gene is characteristic of CML. Four different breakpoint cluster regions (bcr) have been described in BCR. The most common BCR breakpoints, in 95% of CML cases, occur in M-BCR, i.e., introns 13 or 14, resulting in an e13a2 (b2a2) or an e14a2 (b3a2) BCR-ABL1 transcript. “Atypical” transcripts, e8a2, e19a2, e13a3, e14a3, e1a3, and e6a2 BCR-ABL1, account for less than 1% of CML cases [1, 2]. Only 11 CML patients have been reported with the e6a2 variant. A male predominance and a worse outcome have been suggested for this variant [3].

Here, we describe an additional CML case with an e6a2 fusion transcript. This 57-year-old male patient presented with hepatosplenomegaly, weight loss, cough, and fever. Laboratory examination showed a hemoglobin level of 12.1 g/dL, a white blood cell count of 43.5 × 10*9/L with 5% myeloblasts and 10% eosinophils, a platelet count of 129 × 10*9/L, and an LDH of 3,363 U/L (normal value, 313–618 U/L). An abdominal CT scan...


Imatinib Dasatinib Amsacrine Multiplex Reverse Transcription Polymerase Chain Reaction ABL1 Exon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C (2008) A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. Leukemia 22(4):856–858PubMedCrossRefGoogle Scholar
  2. 2.
    Torres F, Ivanova-Dragoeva A, Pereira M, Veiga J, Rodrigues AS, Sousa AB, Tavares P, Fernandes AR (2007) An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation. Leuk Lymphoma 48(5):1034–1037PubMedCrossRefGoogle Scholar
  3. 3.
    Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N (2004) e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica 89(5):611–613PubMedGoogle Scholar
  4. 4.
    Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88(6):2236–2240PubMedGoogle Scholar
  5. 5.
    Dupont M, Jourdan E, Chiesa J (2000) Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML. Leukemia 14(11):2011–2012PubMedCrossRefGoogle Scholar
  6. 6.
    Schultheis B, Wang L, Clark RE, Melo JV (2003) BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia 17(10):2054–2055PubMedCrossRefGoogle Scholar
  7. 7.
    Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C (2005) e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 90(8):1139–1141PubMedGoogle Scholar
  8. 8.
    Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ (2005) E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. Leuk Lymphoma 46(9):1375–1377PubMedCrossRefGoogle Scholar
  9. 9.
    Breccia M, Cannella L, Diverio D, Streponi P, Nanni M, Stefanizzi C, Natalino F, Mecarocci S, Alimena G (2008) Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leuk Res 32(1):177–180PubMedCrossRefGoogle Scholar
  10. 10.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P (2009) Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Acta Haematol 122(1):11–16PubMedCrossRefGoogle Scholar
  11. 11.
    Langabeer SE, Crampe M, Kelly J, Fadalla K, Connaghan G, Conneally E (2010) Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. Leuk Res 34(8):e204–e205PubMedCrossRefGoogle Scholar
  12. 12.
    van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13(12):1901–1928PubMedCrossRefGoogle Scholar
  13. 13.
    Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kahls P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G (2008) Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr 120(21–22):697–709PubMedCrossRefGoogle Scholar
  14. 14.
    Cross NC, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8(1):186–189PubMedGoogle Scholar
  15. 15.
    Jinawath N, Norris-Kirby A, Smith BD, Gocke CD, Batista DA, Griffin CA, Murphy KM (2009) A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia. Diagnostic challenges in clinical laboratory practice. J Mol Diagn 11(4):359–363PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Karolien Anne Beel
    • 1
  • Jan Lemmens
    • 2
  • Hilde Vranckx
    • 3
  • Johan Maertens
    • 1
  • Peter Vandenberghe
    • 3
  1. 1.Department of Hematology, Internal MedicineUniversity Hospital LeuvenLeuvenBelgium
  2. 2.Department of HematologyGZA-ziekenhuizenWilrijkBelgium
  3. 3.Center for Human GeneticsUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations